Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Chemotherapy better for metastatic breast cancer maintenance than durvalumab

Publish date:: December 20, 2019

Key clinical point: Chemotherapy was associated with better progression-free survival (PFS) than durvalumab as maintenance therapy.

Major finding: The median PFS was 2.7 months with durvalumab maintenance vs. 4.4 months with chemotherapy.

Study details: Substudy of a phase 2 trial of 199 patients with metastatic HER2-negative breast cancer.

Disclosures: The study was sponsored by UNICANCER with support from Fondation ARC and AstraZeneca. Dr. Dalenc reported research grants, travel, and/or advisory board activity for AstraZeneca and others.

Citation:

Dalenc F et al. SABCS 2019. Abstract GS3-02.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in Breast Cancer

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Study: Doctors underreport side effects of breast irradiation,

No edge for anastrozole over tamoxifen in DCIS,

Long-term APBI cosmetic, toxicity data reported WBI has the edge Practice-confirming results,

Omitting postop radiotherapy doesn’t affect survival in older breast cancer patients,